Skip to content

A Study to Evaluate Indocyanine Green Lymphangiography to Improve Lymphadenectomy in Gastric Cancer Patients

Indocyanine Green Lymphangiography as a Tool for Improving Lymphadenectomy in Gastric Cancer

Status
Withdrawn
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04591028
Enrollment
0
Registered
2020-10-19
Start date
2022-01-31
Completion date
2022-08-10
Last updated
2023-07-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancer

Brief summary

This study will be looking at the safety and added benefit of using the Indocyanine green dye (ICG) during surgery.

Interventions

DRUGIndocyanine green

A one time injection of IDC prior to the day of scheduled surgery.

Sponsors

Mayo Clinic
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Patients ≥ 18 and ≤ 75 years of age. * Primary gastric adenocarcinoma of any histological subtype confirmed pathologically by endoscopic biopsy. * Clinical stage tumor T1-4a (cT1-4a), N -/+, M0 at preoperative evaluation according to the American Joint Committee on Cancer (AJCC) Cancer Staging Manual Seventh Edition. * No distant metastasis, no direct invasion of adjacent organs such as pancreas and spleen in preoperative exams. * American Society of Anesthesiology score (ASA) class I, II, or III. * Written informed consent.

Exclusion criteria

* Patients ≤ 18 and ≥ 75 years of age. * History of previous upper abdominal surgery (except laparoscopic cholecystectomy). * History of previous gastrectomy, endoscopic mucosal resection or endoscopic submucosal dissection. * History of allergy to iodine agents. * History of other malignant disease within past five years. * Emergency surgery due to complication caused by gastric cancer, such as bleeding obstruction or perforation. * Patients intraoperatively/postoperatively confirmed as T4b. * Patients intraoperatively confirmed as unable to complete D2 lymph node dissection or R0 dissection.

Design outcomes

Primary

MeasureTime frameDescription
Positive ICG fluorescence lymph nodesApproximately 30-90 days after surgeryTotal number of lymph nodes removed after surgery that are positive for ICG fluorescence
Disease positive lymph nodesApproximately 30-90 days after surgeryNumber of ICG positive lymph nodes that are also positive for disease
Number of lymph nodes removed for each lymphatic station of gastrectomyApproximately 30-90 days after surgeryTotal number of lymph nodes removed for each lymphatic station of gastrectomy with NIR+ICG vs gastrectomy without NIR+ICG

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026